These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 303364)
1. Pyoderma gangrenosum with cellular immunity defect and red cell aplasia. Clayton R Proc R Soc Med; 1977 Aug; 70(8):571-2. PubMed ID: 303364 [No Abstract] [Full Text] [Related]
2. Defective monocyte function in pyoderma gangrenosum with IgG kappa paraproteinaemia. Jones RR; Kobza Black A; Donaghy M; Moshtael O; Pinching AJ Clin Exp Immunol; 1983 Jun; 52(3):685-92. PubMed ID: 6409473 [TBL] [Abstract][Full Text] [Related]
3. Pyoderma gangrenosum with altered cellular immunity and dermonecrotic factor. Delescluse J; De Bast C; Achten G Br J Dermatol; 1972 Dec; 87(6):529-32. PubMed ID: 4567639 [No Abstract] [Full Text] [Related]
4. [Dermatitis ulcerosa (pyoderma gangraenosum). 2 cases with abnormal serum factors]. Kovács L; Husz S; Dobozy A; Szarbó E Z Hautkr; 1976 May; 51(09):571-81. PubMed ID: 785845 [No Abstract] [Full Text] [Related]
5. Pyoderma gangrenosum with cellular immunity deficit treated with plasmaphoresis and leukocyte transfusion. Clayton R; Feiwel M; Valdimarsson H Br J Dermatol; 1976 Jul; 95 Suppl 14():67-8. PubMed ID: 1084156 [No Abstract] [Full Text] [Related]
12. [Thymoma and pure red-cell aplasia. Immunologic study of 3 cases]. Estivill X; Soler J; Ayats R; Puig J; González D; Porta F; Domingo-Albós A; Pujol-Moix N Med Clin (Barc); 1985 Jun; 85(4):133-8. PubMed ID: 3875771 [No Abstract] [Full Text] [Related]
13. Idiopathic pyoderma gangrenosum and impaired lymphocyte function: failure of azathioprine and corticosteroid therapy. Breathnach SM; Wells GC; Valdimarsson H Br J Dermatol; 1981 May; 104(5):567-73. PubMed ID: 7236516 [TBL] [Abstract][Full Text] [Related]
14. Hyperimmunoglobulin E and impaired neutrophil functions in a case of pyoderma gangrenosum: effect of clofazimine. Berbis P; Mege JL; Capo C; Kaplanski S; Bongrand P; Privat Y J Am Acad Dermatol; 1988 Mar; 18(3):574-6. PubMed ID: 3351016 [No Abstract] [Full Text] [Related]
15. The current status of pyoderma gangrenosum. Holt PJ Clin Exp Dermatol; 1979 Dec; 4(4):509-16. PubMed ID: 394888 [No Abstract] [Full Text] [Related]
16. Pharmacological modulation of neutrophil phagocytic function in a patient with recurrent sepsis, pyoderma gangrenosum and impaired phagocytosis. Bentley-Phillips CB; Cooper RC; Hallett AF Br J Dermatol; 1982 Jun; 106(6):687-95. PubMed ID: 7082573 [TBL] [Abstract][Full Text] [Related]
17. [Pyoderma gangrenosum: Clofazimine therapy]. Beurey J; Weber M; Delrous JL; Chaulieu Y Ann Dermatol Venereol; 1977 Oct; 104(10):631-4. PubMed ID: 610518 [TBL] [Abstract][Full Text] [Related]
18. Present status of pyoderma gangrenosum. Review of 21 cases. Prystowsky JH; Kahn SN; Lazarus GS Arch Dermatol; 1989 Jan; 125(1):57-64. PubMed ID: 2642682 [TBL] [Abstract][Full Text] [Related]
19. [Immune deficiences during pyoderma gangrenosum associated with a polycythemia vera]. Deschamps P; Leroy D; Dresch C; Michel M Nouv Presse Med; 1977 Jun; 6(26):2339-41. PubMed ID: 887420 [TBL] [Abstract][Full Text] [Related]
20. [Cellular immunity in patients with ulcerous forms of chronic pyoderma undergoing treatment]. Mazina NM; Baltabaev MK Vestn Dermatol Venerol; 1989; (3):48-51. PubMed ID: 2741546 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]